• Skip to primary navigation
  • Skip to main content
  • Skip to primary navigation
  • Skip to main content
Choose which site to search.
University of Arkansas for Medical Sciences Logo University of Arkansas for Medical Sciences
Winthrop P. Rockefeller Cancer Institute
  • UAMS Health
  • Jobs
  • Giving
  • About
    • From the Director
    • Diversity, Equity, and Inclusion
    • Our History
    • Leadership
    • Board of Advisors
    • About Little Rock
    • Maps & Directions
    • Calendar of Events
    • News
  • Patient Care
    • Finding Your Way
    • Treatment
    • Prevention
    • Patient Support
  • Research
    • About
    • Research Training and Education
    • Resources
    • Research Directory
    • Membership
    • Research Activity
  • Get Involved
    • Donate
    • Fundraising Events
    • Volunteer Services & Auxiliary
    • The Envoys
  • College of Medicine
  • Contact
  1. University of Arkansas for Medical Sciences
  2. Winthrop P. Rockefeller Cancer Institute
  3. Dr. Frits van Rhee

Dr. Frits van Rhee

Nonsecretory Multiple Myeloma: New Options in Assessment and Treatment

Hallmark of most multiple myeloma cases is the persistent production of some form of immunoglobulins, a phenomenon that brings the disease to attention. However, there is a subset of multiple myeloma patients who do not secrete immunoglobulin or its component parts into either the blood or urine, hence called non-secretory myeloma. Some non-secretory myeloma patients may produce the immunoglobulin proteins but they have defects in secretion. Due to lack of these protein biomarkers in blood and urine, it may be difficult to assess and treat the disease. Our myeloma panel is talking to Dr. Frits Van Rhee about latest developments and new options available in assessment and treatment of nonsecretory myeloma.  Listen to podcast.

Filed Under: Cancer Featured Stories, Myeloma News, Uncategorized Tagged With: Dr. Frits van Rhee, immunoglobulins, Nonsecretory Multiple Myeloma

Congratulations to Dr. Frits van Rhee on his newest publication

Congratulations to the international expert, our own Dr. Frits van Rhee, on his newest publication, “A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease”.

Be sure to check it out!
Read here on Onctotarget

Filed Under: Cancer Featured Stories, Myeloma News, Uncategorized Tagged With: Dr. Frits van Rhee

Important Lessons Learned from the Measles Virus in Multiple Myeloma

Full MCRI Show: Important Lessons Learned from the Measles Virus in Multiple Myeloma and the Next Step to Advance the Fascinating Viro Therapy with Dr. Frits van Rhee and Dr. Stephen Russell

The measles virus grabbed media attention with one patient’s amazing outcome. Dr. Russell and Dr. van Rhee hope to expand those results into more patients with lessons learned from the first clinical trials.

Be sure to listen to the show or read the transcript from the latest interview with the MyelomaCrowd funding initiative discussing the Measles Virus in Multiple Myeloma and Advancing Viro Therapy with our own Dr. Frits van Rhee and colleague Dr. Stephen Russell!

http://www.myelomacrowd.org/full-vanrhee-russell-measles/

 

Filed Under: Cancer Featured Stories, Myeloma News, Uncategorized Tagged With: Dr. Frits van Rhee, Multiple Myeloma

Winthrop P. Rockefeller Cancer Institute LogoWinthrop P. Rockefeller Cancer InstituteWinthrop P. Rockefeller Cancer Institute
Address: 449 Jack Stephens Dr., Little Rock, AR 72205
Parking Deck: 4018 W Capitol Ave., Little Rock, AR 72205
Appointments : (501) 296-1200
Referring Physicians: (501) 686-6080
  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Pinterest
  • Disclaimer
  • Terms of Use
  • Privacy

© 2023 University of Arkansas for Medical Sciences